Clinicopathologic and molecular features of vascular tumors in a series of 118 cases.
CAMTA1
FOSB
TFE3
Vascular tumors
c-FOS
fluorescence in situ hybridization
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
13
04
2022
entrez:
15
6
2022
pubmed:
16
6
2022
medline:
16
6
2022
Statut:
epublish
Résumé
Vascular tumors are composed of benign, intermediate, and malignant lesions. The diagnosis is challenging because some entities demonstrate overlapping morphologies and harbor the same genetic alterations. We describe herein a cohort of vascular tumors with clinicopathologic, immunohistochemical, and molecular features. 118 vascular tumors including 56 angiosarcomas, 18 epithelioid haemangioendotheliomas (EHE), 25 epithelioid haemangiomas (EH), 8 pseudomyogenic haemangioendotheliomas (PHE), 1 papillary intralymphatic angioendothelioma (PILA), 2 kaposiform haemangioendotheliomas (KHE), 3 Kaposi sarcomas, 2 retiform haemangioendotheliomas (RHE), and 3 anastomosing haemangiomas were assessed. FOSB, c-Fos, CAMTA1, and TFE3 expression and gene rearrangements were analyzed by immunohistochemical staining and FISH, respectively. Our results showed that FOSB expression was diffusely positive in all 8 PHEs, focally or sparsely in 12 EHs, and in 2 angiosarcomas. C-FOS expression was sparsely to diffusely positive in 15 EHs, focally or sparsely in 17 angiosarcomas, 1 EHE, 1 Kaposi sarcoma, and 1 PHE. CAMTA1 expression was positive in only 12 EHEs. TFE3 expression was focally or sparsely positive in all 8 PHEs, 22 angiosarcomas, 6 EHEs, 3 EHs, 2 Kaposi sarcomas, and 2 AHs. FOSB and CAMTA1 are useful diagnostic markers for PHE and EHE, respectively.
Types de publication
Journal Article
Langues
eng
Pagination
2939-2951Informations de copyright
AJTR Copyright © 2022.
Déclaration de conflit d'intérêts
None.
Références
Am J Surg Pathol. 2017 May;41(5):596-606
pubmed: 28009608
Arch Pathol Lab Med. 2020 Feb;144(2):240-244
pubmed: 30958692
Anticancer Res. 2017 Oct;37(10):5441-5447
pubmed: 28982854
Diagn Pathol. 2021 Mar 15;16(1):23
pubmed: 33722245
Am J Surg Pathol. 2019 Dec;43(12):1661-1667
pubmed: 31490237
J Med Case Rep. 2021 Feb 17;15(1):69
pubmed: 33593408
Mod Pathol. 2020 Aug;33(8):1527-1536
pubmed: 32094426
Am J Surg Pathol. 2016 Jan;40(1):94-102
pubmed: 26414223
Am J Surg Pathol. 2011 Feb;35(2):190-201
pubmed: 21263239
Genes Chromosomes Cancer. 2013 Aug;52(8):775-84
pubmed: 23737213
Genes Dev. 2021 Apr 1;35(7-8):495-511
pubmed: 33766984
J Dermatol. 2021 Dec;48(12):1900-1906
pubmed: 34580903
Diagn Pathol. 2015 Aug 28;10:150
pubmed: 26315812
Am J Surg Pathol. 2015 Mar;39(3):394-404
pubmed: 25517951
Histopathology. 2015 Dec;67(6):827-35
pubmed: 25879300
Mod Pathol. 2014 Jan;27 Suppl 1:S30-8
pubmed: 24384851
Elife. 2021 Apr 29;10:
pubmed: 33913810
Mod Pathol. 2014 Jan;27(1):113-27
pubmed: 23828314
J Biol Chem. 2002 Jun 14;277(24):21851-61
pubmed: 11925432
Am J Surg Pathol. 2021 May 1;45(5):690-693
pubmed: 33653978
Am J Transl Res. 2020 Aug 15;12(8):4498-4510
pubmed: 32913523
Adv Exp Med Biol. 2018;1045:357-376
pubmed: 29896675
Mod Pathol. 2019 Oct;32(10):1521-1535
pubmed: 31175325
Diagn Pathol. 2014 Jul 01;9:131
pubmed: 24986479
Am J Surg Pathol. 2015 Oct;39(10):1313-21
pubmed: 26135557
Diagn Pathol. 2013 Sep 24;8:160
pubmed: 24063649
Diagn Pathol. 2020 Dec 9;15(1):139
pubmed: 33298094
Oncol Lett. 2019 Dec;18(6):6355-6360
pubmed: 31788112
Genes Chromosomes Cancer. 2014 Nov;53(11):951-9
pubmed: 25043949